Sami-Sabinsa inaugurates new manufacturing facility for global growth

04-Apr-2023 - Last updated on 04-Apr-2023 at 15:25 GMT

Sami-Sabinsa inaugurates its eighth manufacturing facility © Photo courtesy of Sami-Sabinsa

Sami-Sabinsa Group – parent company to nutraceutical health supplement and herbal extract supplier Sabinsa – inaugurated a new state-of-the-art manufacturing facility in the city of Hassan in southern India.

"This is a milestone for the Sami-Sabinsa group,” said Dr. Muhammed Majeed, chairman and founder of Sami-Sabinsa Group. “With preventive healthcare gaining more prominence worldwide, Sami-Sabinsa Group is gearing up with a new facility to support the wellness of mankind.”

Founded in 1988, the multinational health science company supplies nutraceuticals, cosmeceuticals, standardized herbal extracts, fine chemicals, specialty chemicals and probiotics to the global market.

Innovation and quality standards

Sami-Sabinsa broke ground on the facility in 2020 as part of its strategy to focus on existing ingredient growth and the development of innovative products to boost export sales and double revenue.

Unit I of the facility, the first to come online, is built with an investment of $18 million and is strategically located on ten acres in the Pharma SEZ Industrial Area with easy access to ports on both east and west coasts.

Equipped with 18 reactors (including eight glass-line reactors), two hydrogenators and other specialized equipment like agitated nutsche filter dryers (ANFD), centrifuges and Rotocone Vacuum Dryers, the facility also houses fully equipped quality control and process development labs and features Zero Liquid Discharge (ZLD) technology to minimize the ecological footprint of the production process.

“Innovation and quality standards have always been the core pillars of our growth, which has mapped us globally,” Dr. Majeed added. “The Sami Nutraceuticals facility will be one of the cornerstones of our expansion strategy, enabling the company to bring more new innovations to market."

Production capacity

Unit I has the capacity to produce 88 tons of Active Nutraceutical Ingredients (ANI) and Active PharmaceuticalIngredients (API) a year. It will produce 23 different ingredients and intermediates including Calebin-A, Resveratrol, SabiWhite, Pterostilbene, Cosmoperine, 1, 2- Hexanediol, 1,2-Octanediol, Diindolylmethane (DIM), lndole-3-Carbinol, Ferulic Acid and Urolithins.

Unit II, which is nearing completion, will house three production blocks: one for curcumin and two for multi-purpose herbal extracts.

This is the company’s eighth manufacturing facility, joining six other units in India and one in Utah.